NCT02092948

Phase I Study to evaluate124I-A11 PSCA Minibody in Patients With Metastatic Prostate, Bladder and Pancreatic Cancer

Completed Phase 1 Last updated 27 July 2020

What this trial tests

Phase 1 trial testing [124I] PSCA-Minibody PET/CT imaging of the whole body in Prostate Cancer in 8 participants. Completed in 6 January 2017.

Timeline

22 August 2013

Primary endpoint
6 January 2017

6 January 2017

Quick facts

Lead sponsor	Jonsson Comprehensive Cancer Center
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	8
Start date	22 August 2013
Primary completion	6 January 2017
Estimated completion	6 January 2017
Sites	1 location across United States

Drugs / interventions tested

• [124I] PSCA-Minibody PET/CT imaging of the whole body

Conditions studied

• Prostate Cancer — all drugs for Prostate Cancer →
• Pancreatic Cancer — all drugs for Pancreatic Cancer →
• Bladder Cancer — all drugs for Bladder Cancer →

Sponsor

Jonsson Comprehensive Cancer Center — full company profile →

Who can join

18 and older, any sex, with Prostate Cancer or Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to determine whether positron emission tomography (PET), using the new imaging drug \[124 I\] PSCA-Minibody can be used for imaging prostate, pancreatic or bladder cancer that has spread to the bones and soft tissues (e.g., lymph nodes, lungs, etc.). The PET imaging drug tested in this study binds to the cell marker called Prostate Stem Cell Antigen (PSCA), which is present on certain prostate, pancreatic and bladder cancers.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Emerging new therapeutic antibody derivatives for cancer treatment.
   Jin S, Sun Y, Liang X, Gu X, et al · · 2022 · cited 304× · PMID 35132063 · DOI 10.1038/s41392-021-00868-x
2. Revisiting Immunotherapy: A Focus on Prostate Cancer.
   Cha HR, Lee JH, Ponnazhagan S. · · 2020 · cited 169× · PMID 32066566 · DOI 10.1158/0008-5472.can-19-2948
3. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives.
   Qu J, Mei Q, Chen L, Zhou J. · · 2021 · cited 118× · PMID 33025047 · DOI 10.1007/s00262-020-02735-0
4. PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells.
   Wei X, Lai Y, Li J, Qin L, et al · · 2017 · cited 113× · PMID 28405515 · DOI 10.1080/2162402x.2017.1284722
5. Concise Review: Prostate Cancer Stem Cells: Current Understanding.
   Skvortsov S, Skvortsova II, Tang DG, Dubrovska A. · · 2018 · cited 93× · PMID 29845679 · DOI 10.1002/stem.2859
6. Dual-Modality ImmunoPET/Fluorescence Imaging of Prostate Cancer with an Anti-PSCA Cys-Minibody.
   Tsai WK, Zettlitz KA, Tavaré R, Kobayashi N, et al · · 2018 · cited 30× · PMID 30613270 · DOI 10.7150/thno.27679
7. Significance of PSCA as a novel prognostic marker and therapeutic target for cancer.
   Nayerpour Dizaj T, Doustmihan A, Sadeghzadeh Oskouei B, Akbari M, et al · · 2024 · cited 18× · PMID 38627732 · DOI 10.1186/s12935-024-03320-6
8. Multidisciplinary intervention of early, lethal metastatic prostate cancer: Report from the 2015 Coffey-Holden Prostate Cancer Academy Meeting.
   Miyahira AK, Lang JM, Den RB, Garraway IP, et al · · 2016 · cited 14× · PMID 26477609 · DOI 10.1002/pros.23107